Corpus ID: 53630489

Industry Testing of Opioids for Differential Schedule Control Purposes: Abuse-Deterrent Formulations

@inproceedings{Gauvin2016IndustryTO,
  title={Industry Testing of Opioids for Differential Schedule Control Purposes: Abuse-Deterrent Formulations},
  author={David V Gauvin and Zachary J Zimmermann and James Theodore and H S Baird},
  year={2016}
}
Drug deterrence should not be viewed as “abuse proof” or “diversion proof”. If the abuse deterrent formulation (ADF) provides for a Cmax and half-life of parent compound that is conducive to maintain plasma opiate levels or abate drug withdrawal then compromising of the drug deterrence formulation seems irrelevant to the majority of street consumers those that consume an opiate outside the scope of medical practice. It is an error in judgment to think that all opiate dependent street… CONTINUE READING

Figures from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 59 REFERENCES

Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.

VIEW 1 EXCERPT

Fentanyl patches: preventable overdose.

  • Medicine
  • Prescrire international
  • 2010